Journal Article

Pembrolizumab plus chemotherapy in advanced endometrial cancer: a cost-effectiveness analysis

Bi, Zhenggang, She, Longjiang, Zhao, Xinqiang, Liu, Xiaoning

2025

Overview

Objectives Recently, NRG-GY018 clinical trial demonstrated that adding pembrolizumab to chemotherapy led to significantly longer progression-free survival than chemotherapy alone in the first-line treatment of advanced or recurrent endometrial cancer (a/rEC). This analysis aimed to estimate the cost-effectiveness of pembrolizumab plus paclitaxel plus carboplatin chemotherapy (PC) as the first-line treatment for a/rEC in the US and China. Methods A Markov model based on the clinical data from NRG-GY018 trial was established to estimate the cost and efficacy of PC and paclitaxel plus carboplatin groups for a/rEC in mismatch repair-proficient (pMMR) and mismatch repair–deficient (dMMR) populations. Direct medical costs and utility values were collected from the government databases, local databases, and published literatures. The main outcomes were incremental cost-effectiveness ratios (ICERs), incremental monetary benefit (INMB), and incremental net-health benefit (INHB). The robustness of the model was assessed using one-way and probabilistic sensitivity analyses. Results With the 5-year time horizon, treatment with PC gained an additional 0.87 QALYs (1.34 LYs) in pMMR and 4.17 QALYs (5.14 LYs) in the dMMR population. In the US, the ICERs of PC compared to chemotherapy were 404,575 $/QALY in pMMR and 124,406 $/QALY in dMMR patients, respectively. In China, the ICERs of PC compared to chemotherapy were 220,259 $/QALY and 70,207 $/QALY in pMMR and dMMR populations, respectively. The results of sensitivity analyses supported the robustness of our models. Conclusions For patients with a/rEC, PC was cost-effective compared with chemotherapy in the first-line treatment for dMMR populations in the US. However, the combination of pembrolizumab with chemotherapy was not a cost-effective strategy for pMMR a/rEC in the US and a/rEC in China regardless of the MMR status, a price reduction process is required to reach the traditional cost-effectiveness threshold.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Advanced endometrial cancer / Analysis / Cancer / Cancer therapies / Chemotherapy / Clinical trials / Cost analysis / Cost benefit analysis / Cost-effectiveness analysis / Discount rates / Economic aspects / Endometrial cancer / FDA approval / GDP / Gross Domestic Product / Health Administration / Health care policy / Health Economics / Health Services Research / Immunotherapy / Markov processes / Medical economics / Medicine / Medicine & Public Health / Mortality / Pembrolizumab / Pharmacoeconomics and Health Outcomes / Public Health / Quality of Life Research / Quality-adjusted life years / Software